ALNY vs RPRX
Alnylam Pharmaceuticals, Inc. and Royalty Pharma plc, both Healthcare
Alnylam Pharmaceuticals, Inc. is the larger company at $37B against $30B. On trailing earnings RPRX is the cheaper of the two at a P/E of 32.9 against 121.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year RPRX returned +71% against -45% for ALNY. Ryufin's sector-relative Smart Score puts ALNY ahead, 8/10 against 7/10.
| Figure | ALNY | RPRX |
|---|---|---|
| Last close | $239 | $61.80 |
| Market cap | $37B | $30B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 121.3 | 32.9 |
| 1-year return | -45% | +71% |
| 5-year return | +34% | +87% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 63% of the disclosed total.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 94% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.